New cancer drug trial tests immune system activation
NCT ID NCT03486301
Summary
This early-stage study tested the safety and best dose of a new experimental drug called BDB001, which aims to activate the immune system to fight cancer. It was tested both alone and in combination with an existing immunotherapy drug (pembrolizumab) in 87 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to see how well the treatments were tolerated and to find a safe dose for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlantic Health
Morristown, New Jersey, 07960, United States
-
Florida Cancer Specialists
Sarasota, Florida, 34230, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.